Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by ArtVandelay4on Oct 22, 2012 7:39am
194 Views
Post# 20508948

RE: RE: RE: NioGold, An Attractive Proposition

RE: RE: RE: NioGold, An Attractive Proposition

Hi all,

I have reading these posts for the last year or so and figured it was about time to sign up and take part.  I have been a NOX investor for approx. 2 years - I think it is a great company with great resource potential.

I am still learning much about the TSX Venture and still am confused - I can't understand why the value of NOX since the release of new resource estimate has come so far down, it doesn't make sense.  The only thing I can come up with is that the market expected the resource estimate to include more of phase 2 - although anybody following the stock knew only phase 1 was going to be included.  As well, ARZ has not yet committed to phase 3 which may have some people on edge.  In the end, maybe the most recent decline is because there is nothing to look forward to - no news on the horizon, as the drilling for phase 3 hasn't started and the revised resource estimate with phase 2 data will not be out until the new year.  Anticipation of news seems to spark the TSXV, in this case even with a great resource, new news is bad news - I guess.  Those are just my thoughts on the recent decline - who knows?

<< Previous
Bullboard Posts
Next >>